AstraZeneca and Columbia University Medical Center Sign Strategic Research Collaboration
AstraZeneca and Columbia University Medical Center in New York announced that they have entered into a strategic research collaboration in metabolic related diseases, to develop novel therapeutics primarily in type 2 diabetes and obesity and, with a secondary focus on atherosclerosis (hardening of the arteries)/dyslipidaemia (abnormal blood lipid levels).
Read more ...
Romiplostim Data Show Potential Long-Term Efficacy and Safety
Amgen Inc. (NASDAQ: AMGN) announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts in the blood.
Read more ...
Pfizer Celebrates 5 Years of High-Impact Corporate Volunteer Missions
This summer, Maria Machado, a supply chain expert from Brazil, will make an extended visit to Africa â unlike any trip sheâs taken before. Maria and 15 of her colleagues at Pfizer, Inc. are part of a now 5-year-old skills-based corporate volunteerism program, the Pfizer Global Health Fellows.
Read more ...
Pfizer Completes Acquisition of Encysive Pharmaceuticals Inc.
Pfizer Inc (NYSE:PFE) announced that it has completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ:ENCY) through a merger of Pfizerâs wholly-owned subsidiary, Explorer Acquisition Corp., with and into Encysive. Encysive is now a wholly-owned subsidiary of Pfizer.
Read more ...
First positive health technology assessments for novel oral anticoagulant Pradaxa®
The Scottish Medicines Consortium (SMC) has accepted Pradaxa® (dabigatran etexilate) for routine use within the National Health Service (NHS) of Scotland for its currently licensed indication: the prevention of venous thromboembolic events in adults who have undergone total hip or knee replacement surgery.
Read more ...
GlaxoSmithKline acquires Sirtris Pharmaceuticals, Inc.
GlaxoSmithKline (GSK) announced that it has completed its acquisition of Sirtris Pharmaceuticals, Inc. (Sirtris) for approximately USD720 million (or approx. GBP362 million) through a cash tender offer of USD22.50 (or approx. GBP11.33) per share.
Read more ...
Nycomed sells oncology programs to 4SC
Nycomed agreed with 4SC on the sale of a major part of Nycomed's R&D projects in the field of oncology. Eight projects in the preclinical and first clinical stage will be transferred to 4SC. The agreement is part of Nycomed's strategic decision not to further invest in oncology R&D activities.
Read more ...